



## **For Immediate Release**

### **ALBERTA CHILDREN'S HOSPITAL IN CALGARY OBTAINS VENTRIPOINT'S VMS™ HEART ANALYSIS SYSTEM**

**\*\*\* Clinical Group to Study Advantages of VMS™ in Managing Heart Patients \*\*\***

**SEATTLE, WASHINGTON, June 7, 2011** – VentriPoint Diagnostics Ltd. ("VentriPoint") (TSXV:VPT; Pink OTC:VPTDF.PK) as part of its controlled rollout strategy, is announcing a new VMS™ research site for right heart analysis in Canada at the Alberta Children's Hospital in Calgary. The clinical group will initially be using the VMS™ to look at patients who have had surgery for congenital heart disease, but still have significant problems with the right ventricle and must be followed long-term.

"We are excited to begin using the VMS™ here at the Alberta Children's Hospital. This system has the potential of overcoming some of the obstacles with our current imaging modalities, which we use to assess the right side of the heart," said Dr. Deborah Fruitman, MD, FRCPC, Pediatric Cardiologist at the Alberta Children's Hospital. "We are enthusiastic to see how the VMS™ provides a quick, non-invasive method of assessing the volume and function of the right ventricle that can be followed at every clinic visit. The function of the right ventricle is an essential part in managing many forms of congenital heart disease and we look forward to collaborating with our colleagues in diagnostic imaging and adult congenital cardiology in future research with this imaging system."

VentriPoint's CEO, Dr. George Adams, comments with: "We have a very strong shareholder base in Alberta. I am very pleased to see one of our first systems being placed here. Alberta is very progressive and I expect that many VMS™ systems will be placed in Canada in the next year."

This is the sixth announced installation of the VMS™ heart analysis system. There are currently two in Canada, one in Europe and three in the United States. Additional installations are in process and will be announced, as each system is committed. VentriPoint plans to have ten systems deployed in the US, Europe and Canada by the end of the second quarter of this calendar year.

#### **About Alberta Children's Hospital**

The Alberta Children's Hospital, attends to 75,000 children a year from southern Alberta, southeastern British Columbia and southwestern Saskatchewan. It is a centre of excellence in pediatric health care and a training institution for student doctors, nurses and other health care professionals from teaching programs around the world. The focus is on family-centred care that recognizes the important role families play in the physical, psychological and spiritual well-being of their children.

#### **About VentriPoint Diagnostics Ltd.**

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. The VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multibillion-dollar market potential. Canada and Europe (CE Mark) have



granted approval for the sale of VentriPoint's VMST™ diagnostic tool and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

For further information, please contact:

**VentriPoint Diagnostics Ltd.**

Dr. George Adams, CEO  
Telephone: (206) 283-0221, ext. 401  
email: [gadams@ventripoint.com](mailto:gadams@ventripoint.com)

**Howard Group Inc.**

Peter Weichler/David Burwell  
Telephone: 1.888-221-0915 or 403-221-0915  
email: [Peter@howardgroupinc.com](mailto:Peter@howardgroupinc.com)  
[Dave@howardgroupinc.com](mailto:Dave@howardgroupinc.com)

**Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release**

**FORWARD-LOOKING STATEMENTS:** The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.